Introduction: Multiple sclerosis (MS) is a chronic, unpredictable disease responsible for the occurrence of a variety of neurological symptoms.
Objective: Evaluation of the impact of mood disorders on quality of life in patients with MS treated with immunomodulating drugs.
Material and methods: The study was conducted among 226 MS patients of the mean age 37.32 ± 9.67. In the study, standardized questionnaires were used: the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale (HADS–M) and the MusiQol - International questionnaire investigating quality of life in multiple sclerosis. The results were analyzed statistically.
Results: Anxiety was diagnosed in 51 patients (23%), depression in 13 patients (6%) and irritability and aggression in 117 patients (52%) by HADS - M. The overall score of quality of life measured by MusiQoL was 55.5 ± 12.1 points on a hundred-point scale. Simple linear regression analysis model showed the effect of anxiety and depression symptoms on the quality of life. These variables have been confirmed in a multiple linear regression model.
Conclusions: Mood disorders such as anxiety and depression have a significant negative impact on quality of life in MS patients treated with immunomodulating drugs.

10 - MOOD DISORDERS AND QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS